AMT-190 / uniQure - LARVOL DELTA

CSL Behring Nabs UniQure’s Hemophilia Gene Therapy for up to €1.8B (Labiotech.eu) - "Big pharma CSL Behring will pay the Dutch gene therapy developer uniQure an upfront of €400M...In addition to the €400M upfront, uniQure can expect up to €1.4B as the gene therapy reaches undisclosed regulatory and commercial milestones. The company will also be entitled to royalties of up to around 20% on net sales....The proceeds of the deal will finance the development of uniQure’s gene therapy candidates for liver conditions such as Fabry disease..."

Financing • Fabry Disease • Genetic Disorders